Recombinant Erythropoietin: Payment Options for Medicare

One of 3 reports in the series: Special Report available on this site.

PDF Version Also Available for Download.

Description

Policy interest in Medicare’s payment policies regarding recombinant erythropoietin has arisen chiefly because of the biologic’s expense. Because of concern about the implications of recombinant erythropoietin use for Medicare expenditures, the House Ways and Means Committee, Subcommittee on Health, requested OTA to examine alternative payment policies that Medicare might adopt to pay for the biologic. In responding to that request, this Special Report reviews clinical and economic issues regarding the use of recombinant erythropoietin and develops a series of options for Congressional consideration.

Physical Description

108 p. : ill. ; 28 cm.

Creation Information

United States. Congress. Office of Technology Assessment. May 1990.

Context

This report is part of the collection entitled: Office of Technology Assessment and was provided by UNT Libraries Government Documents Department to Digital Library, a digital repository hosted by the UNT Libraries. It has been viewed 150 times , with 4 in the last month . More information about this report can be viewed below.

Who

People and organizations associated with either the creation of this report or its content.

Provided By

UNT Libraries Government Documents Department

Serving as both a federal and a state depository library, the UNT Libraries Government Documents Department maintains millions of items in a variety of formats. The department is a member of the FDLP Content Partnerships Program and an Affiliated Archive of the National Archives.

Contact Us

What

Descriptive information to help identify this report. Follow the links below to find similar items on the Digital Library.

Titles

  • Main Title: Recombinant Erythropoietin: Payment Options for Medicare
  • Series Title: Special Report

Description

Policy interest in Medicare’s payment policies regarding recombinant erythropoietin has arisen chiefly because of the biologic’s expense. Because of concern about the implications of recombinant erythropoietin use for Medicare expenditures, the House Ways and Means Committee, Subcommittee on Health, requested OTA to examine alternative payment policies that Medicare might adopt to pay for the biologic. In responding to that request, this Special Report reviews clinical and economic issues regarding the use of recombinant erythropoietin and develops a series of options for Congressional consideration.

Physical Description

108 p. : ill. ; 28 cm.

Language

Item Type

Identifier

Unique identifying numbers for this report in the Digital Library or other systems.

Collections

This report is part of the following collection of related materials.

Office of Technology Assessment

The Office of Technology Assessment (OTA) operated from 1972 to 1995, providing Congressional members and committees with analyses of the scientific and technological issues that were increasingly relevant to public policy and legislative action. This collection includes quarterly and annual reports, as well as internal OTA documents such as orientation materials. Many other interesting OTA materials are available in the OTA Legacy Collection via the CyberCemetery.

What responsibilities do I have when using this report?

When

Dates and time periods associated with this report.

Creation Date

  • May 1990

Added to The UNT Digital Library

  • Aug. 20, 2011, 9:15 p.m.

Description Last Updated

  • April 1, 2016, 1:58 p.m.

Usage Statistics

When was this report last used?

Yesterday: 0
Past 30 days: 4
Total Uses: 150

Where

Geographical information about where this report originated or about its content.

Place Name

Publication Place

Map Information

  • map marker Automatically generated Place Name coordinates.
  • map marker Automatically generated Publication Place coordinates.
  • Repositioning map may be required for optimal printing.

Mapped Locations

Interact With This Report

Here are some suggestions for what to do next.

Start Reading

PDF Version Also Available for Download.

Citations, Rights, Re-Use

United States. Congress. Office of Technology Assessment. Recombinant Erythropoietin: Payment Options for Medicare, report, May 1990; [Washington D.C.]. (digital.library.unt.edu/ark:/67531/metadc39668/: accessed July 21, 2017), University of North Texas Libraries, Digital Library, digital.library.unt.edu; crediting UNT Libraries Government Documents Department.